Agency Forms Undergoing Paperwork Reduction Act Review, 52533-52535 [2013-20609]

Download as PDF 52533 Federal Register / Vol. 78, No. 164 / Friday, August 23, 2013 / Notices ESTIMATED ANNUALIZED BURDEN HOURS Form name Jurisdiction Receptionist or Operator ............. Coroner ........................................................... Telephone screener ....................................... National Survey of Medical Examiners and Coroners. National Survey of Medical Examiners and Coroners. Medical Examiner ........................................... LeRoy Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2013–20642 Filed 8–22–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–13–0666] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call (404) 639–7570 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice. Proposed Project National Healthcare Safety Network (NHSN) (OMB No. 0920–0666), exp. 12/ 31/2015—Revision—National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC). Background and Brief Description tkelley on DSK3SPTVN1PROD with NOTICES The National Healthcare Safety Network (NHSN) is a system designed to accumulate, exchange, and integrate relevant information and resources Number of responses per respondent Number of respondents Type of respondent Burden per response (in hr) 800 576 1 1 5/60 30/60 64 1 30/60 forms include component specific monthly reporting plan, prevention process measures monthly monitoring, patient influenza vaccination, and patient influenza vaccination denominator forms. The Outpatient Procedure Component consists of four new forms: Component specific annual survey, monthly reporting plan, event, and monthly denominators and summary forms. Further, the breadth of organism susceptibility data required on all of the healthcare-associated infection (HAI) report forms (i.e., BSI, UTI, SSI, PNEU (VAP and VAE), DE, LTUTI, and MDRO Infection Surveillance) has been reduced for the purposes of streamlining, simplification, and removing undue burden where possible. Significant changes were made to the NHSN Biovigilance Component forms as a result of a subject matter expert and stakeholder working groups. This includes the removal of the monthly incident summary form. A brand new form was added (Form 57.600—State Health Department Validation Record) to collect aggregate validation results that will be gathered by state health departments when conducting facilitylevel validation of NHSN healthcareassociated infection (HAI) data within their jurisdictions using the CDC/NHSN Validation Guidance and Toolkits. Additionally, minor revisions have been made to 32 other forms within the package to clarify and/or update surveillance definitions. The previously approved NSHN package included 48 individual collection forms; the current revision request adds nine new forms and removes one form for a total of 56 forms. The reporting burden will increase by 542,122 hours, for a total of 4,104,776 hours. among private and public stakeholders to support local and national efforts to protect patients and promote healthcare safety. Specifically, the data is used to determine the magnitude of various healthcare-associated adverse events and trends in the rates of these events among patients and healthcare workers with similar risks. The data will be used to detect changes in the epidemiology of adverse events resulting from new and current medical therapies and changing risks. The NHSN consists of six components: Patient Safety, Healthcare Personnel Safety, Biovigilance, LongTerm Care Facility (LTCF), Dialysis, and Outpatient Procedure. The new Dialysis Component was developed in order to separate reporting of dialysis events from the Patient Safety Component. The new component will tailor the NHSN user interface for dialysis users to simplify their data entry and analyses processes as well as provide options for expanding the Dialysis Component in the future to include dialysis surveillance in settings other than outpatient facilities. The new Outpatient Procedure Component was developed to gather data on the impact of infections and other outcomes related to outpatient procedures that are performed in settings such as Ambulatory Surgery Centers (ASCs), Hospital Outpatient Departments (HOPDs), and physicians’ offices. Three event types will be monitored in this new component: Same Day Outcome Measures, Prophylactic Intravenous (IV) Antibiotic Timing, and Surgical Site Infections (SSI). This revision submission includes two new NHSN components and their corresponding forms. The Dialysis Component consists of changes to three previously approved forms and the addition of four new forms. These new ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondents Form No. and name Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... 57.100: NHSN Registration Form ................. 57.101: Facility Contact Information ............. VerDate Mar<15>2010 18:43 Aug 22, 2013 Jkt 229001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 Number of responses per respondent 2,000 2,000 E:\FR\FM\23AUN1.SGM 23AUN1 1 1 Average burden per response (in hrs.) 5/60 10/60 52534 Federal Register / Vol. 78, No. 164 / Friday, August 23, 2013 / Notices ESTIMATED ANNUALIZED BURDEN HOURS—Continued Number of respondents Type of respondents Form No. and name Registered Nurse (Infection Preventionist) .... 57.103: Patient Safety Component—Annual Hospital Survey. 57.105: Group Contact Information .............. 57.106: Patient Safety Monthly Reporting Plan. 57.108: Primary Bloodstream Infection (BSI) 57.111: Pneumonia (PNEU) ......................... 57.112: Ventilator-Associated Event ............. 57.114: Urinary Tract Infection (UTI) ............ 57.116: Denominators for Neonatal Intensive Care Unit (NICU). 57.117: Denominators for Specialty Care Area (SCA)/Oncology (ONC). 57.118: Denominators for Intensive Care Unit (ICU)/Other locations (not NICU or SCA). 57.120: Surgical Site Infection (SSI) ............. 57.121: Denominator for Procedure ............. 57.123: Antimicrobial Use and Resistance (AUR)-Microbiology Data Electronic Upload Specification Tables. 57.124: Antimicrobial Use and Resistance (AUR)-Pharmacy Data Electronic Upload Specification Tables. 57.125: Central Line Insertion Practices Adherence Monitoring. 57.126: MDRO or CDI Infection Form .......... 57.127: MDRO and CDI Prevention Process and Outcome Measures Monthly Monitoring. 57.128: Laboratory-identified MDRO or CDI Event. 57.130: Vaccination Monthly Monitoring Form–Summary Method. 57.131: Vaccination Monthly Monitoring Form–Patient-Level Method. 57.133: Patient Vaccination .......................... 57.137: Long-Term Care Facility Component—Annual Facility Survey. 57.138: Laboratory-identified MDRO or CDI Event for LTCF. 57.139: MDRO and CDI Prevention Process Measures Monthly Monitoring for LTCF. 57.140: Urinary Tract Infection (UTI) for LTCF. 57.141: Monthly Reporting Plan for LTCF .... 57.142: Denominators for LTCF Locations ... 57.143: Prevention Process Measures Monthly Monitoring for LTCF. 57.150: LTAC Annual Survey ....................... 57.151: Rehab Annual Survey ...................... 57.200: Healthcare Personnel Safety Component Annual Facility Survey. 57.203: Healthcare Personnel Safety Monthly Reporting Plan. 57.204: Healthcare Worker Demographic Data. 57.205: Exposure to Blood/Body Fluids ....... 57.206: Healthcare Worker Prophylaxis/ Treatment. 57.207: Follow-Up Laboratory Testing .......... 57.210: Healthcare Worker Prophylaxis/ Treatment-Influenza. 57.300: Hemovigilance Module Annual Survey. 57.301: Hemovigilance Module Monthly Reporting Plan. 57.303: Hemovigilance Module Monthly Reporting Denominators. 57.304: Hemovigilance Adverse Reaction .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Infection Preventionist .................................... Staff RN ......................................................... Staff RN ......................................................... Staff RN ......................................................... Registered Nurse (Infection Preventionist) .... Staff RN ......................................................... Laboratory Technician ................................... Pharmacy Technician .................................... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Registered Nurse (Infection Preventionist) .... Occupational Health RN/Specialist ................ Occupational Health RN/Specialist ................ Occupational Health RN/Specialist ................ Occupational Health RN/Specialist ................ Occupational Health RN/Specialist ................ tkelley on DSK3SPTVN1PROD with NOTICES Laboratory Technician ................................... Occupational Health RN/Specialist ................ Medical/Clinical Laboratory Technologist ...... Medical/Clinical Laboratory Technologist ...... Medical/Clinical Laboratory Technologist ...... Medical/Clinical Laboratory Technologist ...... VerDate Mar<15>2010 18:43 Aug 22, 2013 Jkt 229001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 Number of responses per respondent Average burden per response (in hrs.) 6,000 1 30/60 6,000 6,000 1 12 5/60 35/60 6,000 6,000 6,000 6,000 6,000 36 72 144 27 9 32/60 29/60 22/60 29/60 3 6,000 9 5 6,000 54 5 6,000 6,000 6,000 36 540 12 29/60 5/60 5/60 6,000 12 5/60 1,000 100 5/60 6,000 6,000 72 24 29/60 12/60 6,000 240 15/60 100 5 14 100 5 2 100 250 250 1 10/60 45/60 250 8 15/60 250 12 5/60 250 9 27/60 250 250 250 12 12 12 5/60 3 5/60 400 1,000 50 1 1 1 30/60 25/60 8 50 9 10/60 50 200 20/60 50 50 50 30 1 15/60 50 50 50 50 15/60 10/60 500 1 2 500 12 1/60 500 12 1 500 48 15/60 E:\FR\FM\23AUN1.SGM 23AUN1 52535 Federal Register / Vol. 78, No. 164 / Friday, August 23, 2013 / Notices ESTIMATED ANNUALIZED BURDEN HOURS—Continued Number of respondents Type of respondents Form No. and name Medical/Clinical Laboratory Technologist ...... Staff RN ......................................................... 57.305: Hemovigilance Incident .................... 57.400: Outpatient Procedure Component— Annual Facility Survey. 57.401: Outpatient Procedure Component— Monthly Reporting Plan. 57.402: Outpatient Procedure Component Event. 57.403: Outpatient Procedure Component— Monthly Denominators and Summary. 57.500: Outpatient Dialysis Center Practices Survey. 57.501: Dialysis Monthly Reporting Plan ...... 57.502: Dialysis Event .................................. 57.503: Denominator for Outpatient Dialysis 57.504: Prevention Process Measures Monthly Monitoring for Dialysis. 57.505: Dialysis Patient Influenza Vaccination. 57.506: Dialysis Patient Influenza Vaccination Denominator. 57.600: State Health Department Validation Record. Staff RN ......................................................... Staff RN ......................................................... Staff RN ......................................................... Registered Nurse (Infection Preventionist) .... Staff Staff Staff Staff RN RN RN RN ......................................................... ......................................................... ......................................................... ......................................................... Staff RN ......................................................... Staff RN ......................................................... Epidemiologist ................................................ Kimberly S. Lane, Deputy Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2013–20609 Filed 8–22–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention tkelley on DSK3SPTVN1PROD with NOTICES Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns Impact of Japanese Encephalitis Vaccination in Cambodia, Funding Opportunity Announcement (FOA) CK14–001, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 1:00 p.m.–3:00 p.m., October 17, 2013 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters To Be Discussed: The meeting will include the initial review, VerDate Mar<15>2010 18:43 Aug 22, 2013 Jkt 229001 discussion, and evaluation of applications received in response to ‘‘Impact of Japanese Encephalitis Vaccination in Cambodia, FOA CK14– 001’’. Contact Person for More Information: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718– 8833. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2013–20531 Filed 8–22–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0002] Withdrawal of Approval of New Animal Drug Applications; Quali-Tech Products, Inc.; Bambermycins; Pyrantel; Tylosin; Virginiamycin AGENCY: Food and Drug Administration, HHS. PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 Number of responses per respondent Average burden per response (in hrs.) 500 5,000 12 1 10/60 5/60 5,000 12 15/60 5,000 25 40/60 5,000 12 40/60 6,000 1 6,000 6,000 6,000 600 12 60 12 12 5/60 13/60 6/60 30/60 250 75 10/60 250 5 10/60 152 50 15/60 ACTION: 1.75 Notice. The Food and Drug Administration (FDA) is withdrawing approval of four new animal drug applications (NADAs) held by QualiTech Products, Inc., at the sponsor’s request because the products are no longer manufactured or marketed. DATES: Withdrawal of approval is effective September 3, 2013. FOR FURTHER INFORMATION CONTACT: David Alterman, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855; 240–453–6843; email: david.alterman@fda.hhs.gov. SUPPLEMENTARY INFORMATION: QualiTech Products, Inc., has requested that FDA withdraw approval of the following four NADAs because the products, used to manufacture Type C medicated feeds, are no longer manufactured or marketed: NADA 097– 980 for Quali-Tech TYLAN–10 (tylosin phosphate) Premix, NADA 118–815 for Q.T. BAN–TECH (pyrantel tartrate), NADA 132–705 for FLAVOMYCIN (bambermycins), and NADA 133–335 for STAFAC (virginiamycin) Swine Pak 10. Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 097–980, 118–815, 132–705, and 133–335, and all supplements and SUMMARY: E:\FR\FM\23AUN1.SGM 23AUN1

Agencies

[Federal Register Volume 78, Number 164 (Friday, August 23, 2013)]
[Notices]
[Pages 52533-52535]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20609]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-13-0666]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
(404) 639-7570 or send an email to omb@cdc.gov. Send written comments
to CDC Desk Officer, Office of Management and Budget, Washington, DC
20503 or by fax to (202) 395-5806. Written comments should be received
within 30 days of this notice.

Proposed Project

National Healthcare Safety Network (NHSN) (OMB No. 0920-0666), exp.
12/31/2015--Revision--National Center for Emerging and Zoonotic
Infectious Diseases (NCEZID), Centers for Disease Control and
Prevention (CDC).

Background and Brief Description

The National Healthcare Safety Network (NHSN) is a system designed
to accumulate, exchange, and integrate relevant information and
resources among private and public stakeholders to support local and
national efforts to protect patients and promote healthcare safety.
Specifically, the data is used to determine the magnitude of various
healthcare-associated adverse events and trends in the rates of these
events among patients and healthcare workers with similar risks. The
data will be used to detect changes in the epidemiology of adverse
events resulting from new and current medical therapies and changing
risks. The NHSN consists of six components: Patient Safety, Healthcare
Personnel Safety, Biovigilance, Long-Term Care Facility (LTCF),
Dialysis, and Outpatient Procedure.
The new Dialysis Component was developed in order to separate
reporting of dialysis events from the Patient Safety Component. The new
component will tailor the NHSN user interface for dialysis users to
simplify their data entry and analyses processes as well as provide
options for expanding the Dialysis Component in the future to include
dialysis surveillance in settings other than outpatient facilities.
The new Outpatient Procedure Component was developed to gather data
on the impact of infections and other outcomes related to outpatient
procedures that are performed in settings such as Ambulatory Surgery
Centers (ASCs), Hospital Outpatient Departments (HOPDs), and
physicians' offices. Three event types will be monitored in this new
component: Same Day Outcome Measures, Prophylactic Intravenous (IV)
Antibiotic Timing, and Surgical Site Infections (SSI).
This revision submission includes two new NHSN components and their
corresponding forms. The Dialysis Component consists of changes to
three previously approved forms and the addition of four new forms.
These new forms include component specific monthly reporting plan,
prevention process measures monthly monitoring, patient influenza
vaccination, and patient influenza vaccination denominator forms. The
Outpatient Procedure Component consists of four new forms: Component
specific annual survey, monthly reporting plan, event, and monthly
denominators and summary forms.
Further, the breadth of organism susceptibility data required on
all of the healthcare-associated infection (HAI) report forms (i.e.,
BSI, UTI, SSI, PNEU (VAP and VAE), DE, LTUTI, and MDRO Infection
Surveillance) has been reduced for the purposes of streamlining,
simplification, and removing undue burden where possible. Significant
changes were made to the NHSN Biovigilance Component forms as a result
of a subject matter expert and stakeholder working groups. This
includes the removal of the monthly incident summary form. A brand new
form was added (Form 57.600--State Health Department Validation Record)
to collect aggregate validation results that will be gathered by state
health departments when conducting facility-level validation of NHSN
healthcare-associated infection (HAI) data within their jurisdictions
using the CDC/NHSN Validation Guidance and Toolkits.
Additionally, minor revisions have been made to 32 other forms
within the package to clarify and/or update surveillance definitions.
The previously approved NSHN package included 48 individual
collection forms; the current revision request adds nine new forms and
removes one form for a total of 56 forms. The reporting burden will
increase by 542,122 hours, for a total of 4,104,776 hours.

Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form No. and name Number of responses per per response
respondents respondent (in hrs.)
----------------------------------------------------------------------------------------------------------------
Registered Nurse (Infection 57.100: NHSN 2,000 1 5/60
Preventionist). Registration Form.
Registered Nurse (Infection 57.101: Facility Contact 2,000 1 10/60
Preventionist). Information.

[[Page 52534]]

Registered Nurse (Infection 57.103: Patient Safety 6,000 1 30/60
Preventionist). Component--Annual
Hospital Survey.
Registered Nurse (Infection 57.105: Group Contact 6,000 1 5/60
Preventionist). Information.
Registered Nurse (Infection 57.106: Patient Safety 6,000 12 35/60
Preventionist). Monthly Reporting Plan.
Registered Nurse (Infection 57.108: Primary 6,000 36 32/60
Preventionist). Bloodstream Infection
(BSI).
Registered Nurse (Infection 57.111: Pneumonia (PNEU) 6,000 72 29/60
Preventionist).
Registered Nurse (Infection 57.112: Ventilator- 6,000 144 22/60
Preventionist). Associated Event.
Infection Preventionist............... 57.114: Urinary Tract 6,000 27 29/60
Infection (UTI).
Staff RN.............................. 57.116: Denominators for 6,000 9 3
Neonatal Intensive Care
Unit (NICU).
Staff RN.............................. 57.117: Denominators for 6,000 9 5
Specialty Care Area
(SCA)/Oncology (ONC).
Staff RN.............................. 57.118: Denominators for 6,000 54 5
Intensive Care Unit
(ICU)/Other locations
(not NICU or SCA).
Registered Nurse (Infection 57.120: Surgical Site 6,000 36 29/60
Preventionist). Infection (SSI).
Staff RN.............................. 57.121: Denominator for 6,000 540 5/60
Procedure.
Laboratory Technician................. 57.123: Antimicrobial 6,000 12 5/60
Use and Resistance
(AUR)-Microbiology Data
Electronic Upload
Specification Tables.
Pharmacy Technician................... 57.124: Antimicrobial 6,000 12 5/60
Use and Resistance
(AUR)-Pharmacy Data
Electronic Upload
Specification Tables.
Registered Nurse (Infection 57.125: Central Line 1,000 100 5/60
Preventionist). Insertion Practices
Adherence Monitoring.
Registered Nurse (Infection 57.126: MDRO or CDI 6,000 72 29/60
Preventionist). Infection Form.
Registered Nurse (Infection 57.127: MDRO and CDI 6,000 24 12/60
Preventionist). Prevention Process and
Outcome Measures
Monthly Monitoring.
Registered Nurse (Infection 57.128: Laboratory- 6,000 240 15/60
Preventionist). identified MDRO or CDI
Event.
Registered Nurse (Infection 57.130: Vaccination 100 5 14
Preventionist). Monthly Monitoring Form-
Summary Method.
Registered Nurse (Infection 57.131: Vaccination 100 5 2
Preventionist). Monthly Monitoring Form-
Patient-Level Method.
Registered Nurse (Infection 57.133: Patient 100 250 10/60
Preventionist). Vaccination.
Registered Nurse (Infection 57.137: Long-Term Care 250 1 45/60
Preventionist). Facility Component--
Annual Facility Survey.
Registered Nurse (Infection 57.138: Laboratory- 250 8 15/60
Preventionist). identified MDRO or CDI
Event for LTCF.
Registered Nurse (Infection 57.139: MDRO and CDI 250 12 5/60
Preventionist). Prevention Process
Measures Monthly
Monitoring for LTCF.
Registered Nurse (Infection 57.140: Urinary Tract 250 9 27/60
Preventionist). Infection (UTI) for
LTCF.
Registered Nurse (Infection 57.141: Monthly 250 12 5/60
Preventionist). Reporting Plan for LTCF.
Registered Nurse (Infection 57.142: Denominators for 250 12 3
Preventionist). LTCF Locations.
Registered Nurse (Infection 57.143: Prevention 250 12 5/60
Preventionist). Process Measures
Monthly Monitoring for
LTCF.
Registered Nurse (Infection 57.150: LTAC Annual 400 1 30/60
Preventionist). Survey.
Registered Nurse (Infection 57.151: Rehab Annual 1,000 1 25/60
Preventionist). Survey.
Occupational Health RN/Specialist..... 57.200: Healthcare 50 1 8
Personnel Safety
Component Annual
Facility Survey.
Occupational Health RN/Specialist..... 57.203: Healthcare 50 9 10/60
Personnel Safety
Monthly Reporting Plan.
Occupational Health RN/Specialist..... 57.204: Healthcare 50 200 20/60
Worker Demographic Data.
Occupational Health RN/Specialist..... 57.205: Exposure to 50 50 1
Blood/Body Fluids.
Occupational Health RN/Specialist..... 57.206: Healthcare 50 30 15/60
Worker Prophylaxis/
Treatment.
Laboratory Technician................. 57.207: Follow-Up 50 50 15/60
Laboratory Testing.
Occupational Health RN/Specialist..... 57.210: Healthcare 50 50 10/60
Worker Prophylaxis/
Treatment-Influenza.
Medical/Clinical Laboratory 57.300: Hemovigilance 500 1 2
Technologist. Module Annual Survey.
Medical/Clinical Laboratory 57.301: Hemovigilance 500 12 1/60
Technologist. Module Monthly
Reporting Plan.
Medical/Clinical Laboratory 57.303: Hemovigilance 500 12 1
Technologist. Module Monthly
Reporting Denominators.
Medical/Clinical Laboratory 57.304: Hemovigilance 500 48 15/60
Technologist. Adverse Reaction.

[[Page 52535]]

Medical/Clinical Laboratory 57.305: Hemovigilance 500 12 10/60
Technologist. Incident.
Staff RN.............................. 57.400: Outpatient 5,000 1 5/60
Procedure Component--
Annual Facility Survey.
Staff RN.............................. 57.401: Outpatient 5,000 12 15/60
Procedure Component--
Monthly Reporting Plan.
Staff RN.............................. 57.402: Outpatient 5,000 25 40/60
Procedure Component
Event.
Staff RN.............................. 57.403: Outpatient 5,000 12 40/60
Procedure Component--
Monthly Denominators
and Summary.
Registered Nurse (Infection 57.500: Outpatient 6,000 1 1.75
Preventionist). Dialysis Center
Practices Survey.
Staff RN.............................. 57.501: Dialysis Monthly 6,000 12 5/60
Reporting Plan.
Staff RN.............................. 57.502: Dialysis Event.. 6,000 60 13/60
Staff RN.............................. 57.503: Denominator for 6,000 12 6/60
Outpatient Dialysis.
Staff RN.............................. 57.504: Prevention 600 12 30/60
Process Measures
Monthly Monitoring for
Dialysis.
Staff RN.............................. 57.505: Dialysis Patient 250 75 10/60
Influenza Vaccination.
Staff RN.............................. 57.506: Dialysis Patient 250 5 10/60
Influenza Vaccination
Denominator.
Epidemiologist........................ 57.600: State Health 152 50 15/60
Department Validation
Record.
----------------------------------------------------------------------------------------------------------------

Kimberly S. Lane,
Deputy Director, Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2013-20609 Filed 8-22-13; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.